INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

Resources

Resources available to you to support your patients.

PODCARE+

Learn about a centralized patient support program for your eligible patients being treated with TOBI Podhaler.

Savings and Support

Share

To share this website with other health care professionals, please choose your email service provider:

This site is intended for US healthcare professionals. By clicking "continue" you acknowledge that you are a US healthcare professional.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.